Article ; Online: Treatment Patterns of Long-Acting Somatostatin Analogs for Neuroendocrine Tumors
Journal of Health Economics and Outcomes Research (2023)
2023
Abstract: Background:** Long-acting somatostatin analog therapy (LA-SSA) is recommended as first-line therapy for treatment of unresectable or metastatic neuroendocrine tumors (NETs). Understanding treatment sequencing and dosing patterns of LA-SSA is essential ... ...
| Abstract | **Background:** Long-acting somatostatin analog therapy (LA-SSA) is recommended as first-line therapy for treatment of unresectable or metastatic neuroendocrine tumors (NETs). Understanding treatment sequencing and dosing patterns of LA-SSA is essential for clinical decision-making to provide value-based management of NETs. **Objective:** To describe treatment patterns of LA-SSA among patients with NETs and subgroups with carcinoid syndrome (CS) in the United States. **Methods:** This retrospective study utilized claims data from MarketScan® databases to identify patients with NETs and newly treated with LA-SSA between January 1, 2015, and October 31, 2020. Patients were stratified by index LA-SSA (lanreotide and octreotide long-acting release \[LAR\]). Reported 28-day doses were based on claim fields for days’ supply/drug quantity or units of service. Dose escalation was defined as increases in quantity or frequency. Continuous variables, categorical variables, and Kaplan-Meier estimated treatment durations were compared using _t_-tests, chi-square/Fisher’s tests, and log-rank tests, respectively. **Results:** The study included 241 lanreotide and 521 octreotide LAR patients. Compared with octreotide LAR patients, treatment duration was longer for lanreotide patients (median, 41.3 vs 26.8 months; log-rank _p_=.004). Fewer lanreotide patients received rescue treatment with short-acting octreotide (7.9% vs 14.4%; _p_=.011), and a first (6.2% vs 27.3%) and second dose escalation (0.8% vs 5.2%; both _p_<.05). Among patients with doses reported, fewer lanreotide patients received above-label doses (2.5% \[5/202\] vs 14.4% \[60/416\]; _p_<.001). Among patients who ended treatment during follow-up, fewer lanreotide patients transitioned to another LA-SSA (18.9% \[17/90\] vs 33.6% \[92/274\]; _p_=.008). Similar treatment patterns were observed in CS subgroups. Results for switched treatment patterns were limited due to insufficient sample sizes. **Discussion:** Real-world treatment patterns of LA-SSA were ... |
|---|---|
| Keywords | Computer applications to medicine. Medical informatics ; R858-859.7 |
| Subject code | 616 ; 610 |
| Language | English |
| Publishing date | 2023-12-01T00:00:00Z |
| Publisher | Columbia Data Analytics, LLC |
| Document type | Article ; Online |
| Database | BASE - Bielefeld Academic Search Engine (life sciences selection) |
Full text online
More links
Kategorien
Inter-library loan at ZB MED
Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.